TY  - JOUR
AU  - Martin-Broto, Javier
AU  - Lopez-Pousa, Antonio 
AU  - Brohl, Andrew S
AU  - Van-Tine, Brian A
AU  - Powers, Benjamin
AU  - Stacchiotti, Silvia
AU  - Blay, Jean-Yves
AU  - Hu, James S
AU  - Oakley, Gerard J
AU  - Wang, Hong
AU  - Szpurka, Anna M
AU  - Levy, Donna E
AU  - Mo, Gary
AU  - Ceccarelli, Matteo
AU  - Jones, Robin L
PY  - 2020
DO  - 10.1158/1535-7163.MCT-20-0441
UR  - http://hdl.handle.net/10668/16589
T2  - Molecular cancer therapeutics
AB  - This phase Ib study enumerated whole blood circulating tumor cells (CTC) and evaluated biomarkers in patients with potentially resectable soft-tissue sarcoma (STS) treated with olaratumab monotherapy (20 mg/kg) for one cycle followed by up to six...
LA  - en
PB  - American Association for Cancer Research
KW  - Adult
KW  - Biomarkers, Tumor
KW  - Doxorubicin
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Platelet-Derived Growth Factor
KW  - Positron-Emission Tomography
KW  - Receptor, Platelet-Derived Growth Factor beta
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - Female
KW  - Kaplan-Meier Estimate
KW  - Ligands
KW  - Neoplastic Cells, Circulating
KW  - Receptor, Platelet-Derived Growth Factor alpha
KW  - Sarcoma
KW  - Treatment Outcome
TI  - Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
TY  - research article
VL  - 20
ER  -